Ophthalmology
Cloudbreak Pharma Reports Positive Top-Line Phase 3 Data for CBT-001 in Pterygium Treatment
Cloudbreak Pharma Inc. (HKEX: 2592), a clinical-stage ophthalmic biopharmaceutical company specializing in proprietary Multi Kinase Inhibitor (MKI) di
